Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Traws Pharma, Inc. (TRAW)
USD0.65
-0.05 (-7.15%)
US NASDAQ Healthcare Biotechnology
Address
12 Penns Trail 18940
Newtown, PA, US
Newtown, PA, US
CEO
Iain D. Dukes
Website
trawspharma.com
IPO
2013-07-25
CIK 1130598 ISIN US68232V8845
Also trades on
NASDAQ Capital Market · ONTX (USD)
NASDAQ Capital Market · ONTXW (USD)
NASDAQ Global Market · TRAW (USD)
Description
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.65
-0.05 (-7.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.45
Float Shares
5.96M
Free Float %
65.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +15.34% | -15.32% | +50.40% | -4.08% | -9.62% | +66.37% | +40.30% | -93.40% | -99.19% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.65
Low
8.00
+1,122.5%
Consensus
8.00
+1,122.5%
Median
8.00
+1,122.5%
High
8.00
+1,122.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
8.00
+1,122.5%
|
| All Time | 1 |
8.00
+1,122.5%
|
Quality scores
Altman Z-Score
-120.80
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+1,134.5% ★ Q1'26: -100.0% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+102.3% ★ Q1'26: +91.0% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-713.4%
-
EBIT margin Biotechnology: +0.0%-640.7%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+439.5% Q1'26: +1,164.1% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q2'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.46M
est: 3.20M (+258.3%)
|
5.55M
est: 5.89M (-5.8%)
|
787.0K
est: 845.5K (-6.9%)
|
1.23M
est: 1.30M (-5.3%)
|
2.18M
est: 2.21M (-1.0%)
|
231.0K
est: 210.8K (+9.6%)
|
226.0K
est: 232.0K (-2.6%)
|
226.0K
est: 207.5K (+8.9%)
|
226.0K
est: 215.3K (+5.0%)
|
226.0K
est: 230.0K (-1.7%)
|
2.79M
est: 2.80M (-0.4%)
|
300.0K
300.0K – 300.0K
-89.3% YoY
|
13.10M
13.10M – 13.10M
+4,266.7% YoY
|
57.10M
57.10M – 57.10M
+335.9% YoY
|
153.70M
153.70M – 153.70M
+169.2% YoY
|
| EBITDA |
-23.86M
est: -3.20M (-646.2%)
|
-19.56M
est: -5.89M (-232.2%)
|
-23.99M
est: -845.5K (-2,737.5%)
|
-20.48M
est: -1.30M (-1,479.6%)
|
-21.69M
est: -2.21M (-883.3%)
|
-24.98M
est: -210.8K (-11,752.9%)
|
-16.48M
est: -232.0K (-7,004.3%)
|
-19.61M
est: -207.5K (-9,352.0%)
|
-20.28M
est: -215.3K (-9,318.9%)
|
-166.51M
est: -230.0K (-72,296.1%)
|
-17.81M
est: -2.80M (-536.2%)
|
-300.0K
-300.0K – -300.0K
+89.3% YoY
|
-13.10M
-13.10M – -13.10M
-4,266.7% YoY
|
-57.10M
-57.10M – -57.10M
-335.9% YoY
|
-153.70M
-153.70M – -153.70M
-169.2% YoY
|
| EBIT |
-24.01M
est: -3.20M (-650.9%)
|
-19.65M
est: -5.89M (-233.9%)
|
-24.08M
est: -845.5K (-2,747.9%)
|
-20.53M
est: -1.30M (-1,483.8%)
|
-21.70M
est: -2.21M (-883.9%)
|
-24.99M
est: -210.8K (-11,759.1%)
|
-16.50M
est: -232.0K (-7,010.3%)
|
-19.63M
est: -207.5K (-9,358.8%)
|
-20.30M
est: -215.3K (-9,326.3%)
|
-166.52M
est: -230.0K (-72,301.3%)
|
-17.88M
est: -2.80M (-538.4%)
|
-300.0K
-300.0K – -300.0K
+89.3% YoY
|
-13.10M
-13.10M – -13.10M
-4,266.7% YoY
|
-57.10M
-57.10M – -57.10M
-335.9% YoY
|
-153.70M
-153.70M – -153.70M
-169.2% YoY
|
| Net Income |
-23.98M
est: -130.13B (+100.0%)
|
-19.67M
est: -39.83B (+100.0%)
|
-24.09M
est: -24.59B (+99.9%)
|
-20.57M
est: -3.35B (+99.4%)
|
-21.50M
est: -1.02B (+97.9%)
|
-25.16M
est: -80.06M (+68.6%)
|
-16.16M
est: -35.71M (+54.7%)
|
-18.96M
est: -35.91M (+47.2%)
|
-18.95M
est: -37.14M (+49.0%)
|
-54.67M
est: -1.29B (+95.8%)
|
9.17M
est: 5.78M (+58.7%)
|
-26.25M
-28.40M – -24.10M
-554.2% YoY
|
-33.69M
-49.45M – -17.92M
-28.3% YoY
|
-5.78M
-5.78M – -5.78M
+82.8% YoY
|
4.10M
4.10M – 4.10M
+171.0% YoY
|
| SGA |
9.38M
est: 134.11M (-93.0%)
|
9.08M
est: 246.92M (-96.3%)
|
7.41M
est: 35.47M (-79.1%)
|
7.59M
est: 54.39M (-86.1%)
|
8.35M
est: 92.51M (-91.0%)
|
8.33M
est: 8.84M (-5.8%)
|
9.43M
est: 9.73M (-3.2%)
|
8.45M
est: 8.70M (-3.0%)
|
9.09M
est: 9.03M (+0.7%)
|
12.29M
est: 8.13M (+51.1%)
|
8.52M
est: 98.98M (-91.4%)
|
10.60M
10.60M – 10.60M
-89.3% YoY
|
463.08M
463.08M – 463.08M
+4,266.7% YoY
|
2.02B
2.02B – 2.02B
+335.9% YoY
|
5.43B
5.43B – 5.43B
+169.2% YoY
|
| EPS |
-59,062.00
est: -83,812.50 (+29.5%)
|
-24,975.00
est: -25,649.95 (+2.6%)
|
-15,056.00
est: -15,834.35 (+4.9%)
|
-1,870.69
est: -2,154.38 (+13.2%)
|
-560.58
est: -658.75 (+14.9%)
|
-54.21
est: -51.56 (-5.1%)
|
-24.01
est: -23.00 (-4.4%)
|
-22.68
est: -23.13 (+1.9%)
|
-22.57
est: -23.92 (+5.6%)
|
-35.21
est: -154.35 (+77.2%)
|
0.83
est: 0.69 (+20.3%)
|
-3.14
-3.39 – -2.88
-555.1% YoY
|
-4.03
-5.90 – -2.14
-28.3% YoY
|
-0.69
-0.69 – -0.69
+82.9% YoY
|
0.49
0.49 – 0.49
+171.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.59B
OE per share TTM
-247.63
Owner's Yield
-12,940.66%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
364.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alex Noah Investors, Inc. | 13.64M | 6.52% | — | 13.64M | — | — | CO | Illinois | 2021-01-08 | ↗ |
| 2 | Jonathan I. Cope | 13.64M | 6.52% | — | 13.64M | — | — | IN | United States | 2021-01-08 | ↗ |
| 3 | Joshua B. Scheinfeld | 13.64M | 6.52% | — | 13.64M | — | — | IN | United States | 2021-01-08 | ↗ |
| 4 | Lincoln Park Capital Fund, LLC | 13.64M | 6.52% | — | 13.64M | — | — | OO | Illinois | 2021-01-08 | ↗ |
| 5 | Lincoln Park Capital, LLC | 13.64M | 6.52% | — | 13.64M | — | — | OO | Illinois | 2021-01-08 | ↗ |
| 6 | Rockledge Capital Corporation | 13.64M | 6.52% | — | 13.64M | — | — | CO | Texas | 2021-01-08 | ↗ |
| 7 | EcoR1 Capital, LLC | 7.56M | 11.00% | — | 7.56M | — | 7.56M | OO | Delaware | 2018-05-07 | ↗ |
| 8 | Oleg Nodelman | 7.56M | 11.00% | — | 7.56M | — | 7.56M | IN | United States | 2018-05-07 | ↗ |
| 9 | Armistice Capital Master Fund Ltd. | 7.29M | 4.99% | — | 7.29M | — | 7.29M | CO | Delaware | 2020-01-10 | ↗ |
| 10 | Armistice Capital, LLC | 7.29M | 4.99% | — | 7.29M | — | 7.29M | IA, OO | Delaware | 2020-01-10 | ↗ |
| 11 | Steven Boyd | 7.29M | 4.99% | — | 7.29M | — | 7.29M | HC, IN | Delaware | 2020-01-10 | ↗ |
| 12 | EcoR1 Capital Fund Qualified, L.P. | 6.20M | 11.00% | — | 6.20M | — | 6.20M | PN | Delaware | 2018-05-07 | ↗ |
| 13 | Point72 Asset Management, L.P. | 3.00M | 4.00% | — | 3.00M | — | 3.00M | PN | Citizenship or place of organization Delaware | 2020-02-14 | ↗ |
| 14 | Point72 Capital Advisors, Inc. | 3.00M | 4.00% | — | 3.00M | — | 3.00M | CO | Citizenship or place of organization Delaware | 2020-02-14 | ↗ |
| 15 | Steven A. Cohen | 3.00M | 4.00% | — | 3.00M | — | 3.00M | IN | Citizenship or place of organization United States | 2020-02-14 | ↗ |
| 16 | Nikolay Savchuk | 2.93M | 11.60% | 66.7K | 2.87M | 66.7K | 10.00 | IN | United States | 2024-04-08 | ↗ |
| 17 | Iain D. Dukes | 1.71M | 6.80% | 66.7K | 1.65M | 66.7K | 10.00 | IN | United Kingdom | 2024-04-08 | ↗ |
| 18 | Viriom, Inc. | 1.65M | 6.50% | — | 1.65M | — | 10.00 | CO | Maryland | 2024-04-08 | ↗ |
| 19 | Heights Capital Management, Inc. | 1.18M | 5.70% | — | 1.18M | — | 1.18M | CO | Cayman Islands | 2021-10-01 | ↗ |
| 20 | OrbiMed Advisors LLC | 602.0K | 19.90% | — | 602.0K | — | 10.00 | IA | Delaware | 2024-09-23 | ↗ |
| 21 | OrbiMed Capital GP VIII LLC | 602.0K | 19.90% | — | 602.0K | — | 10.00 | OO | Delaware | 2024-09-23 | ↗ |
| 22 | 683 Capital Management, LLC | 593.3K | 9.70% | — | 593.3K | — | 10.00 | IA | Delaware | 2019-09-20 | ↗ |
| 23 | 683 Capital Partners, LP | 593.3K | 9.70% | 593.3K | — | 593.3K | 10.00 | PN | Delaware | 2019-09-20 | ↗ |
| 24 | Ari Zweiman | 593.3K | 9.70% | — | 593.3K | — | 10.00 | IN | United States of America | 2019-09-20 | ↗ |
| 25 | Baxalta GmbH | 260.3K | 3.85% | — | 260.3K | — | — | CO | Switzerland | 2017-02-06 | ↗ |
| 26 | Baxalta Incorporated | 260.3K | 3.85% | — | 260.3K | — | — | CO | Delaware | 2017-02-06 | ↗ |
| 27 | Shire plc | 260.3K | 3.85% | — | 260.3K | — | — | CO | Jersey, Channel Islands | 2017-02-06 | ↗ |
| 28 | Tyndall Capital Partners, L.P. | 26.0K | 0.10% | 26.0K | — | 26.0K | — | PN | State of Delaware | 2020-02-14 | ↗ |
| 29 | CVI Investments, Inc. | — | 0.00% | — | — | — | — | CO | OR PLACE OF ORGANIZATION | 2022-02-14 | ↗ |
| 30 | Heights Capital Management, Inc. | — | 0.00% | — | — | — | — | CO | OR PLACE OF ORGANIZATION | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-9 vs prev Q
New positions
9
Closed positions
18
Increased
9
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 730.0K +400.0K (+121.2%) | 824.9K +214.4K (+35.1%) | 12.54% +6.872 pp | 0.00% +0.000 pp | USD1.66 -31.9% | 4 qtrs — |
| 2 | — | 713.5K +713.5K (+100.0%) | 806.3K +806.3K (+100.0%) | 12.26% +12.258 pp | 0.34% +0.342 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 3 | IKARIAN CAPITAL, LLC | 678.1K +649.6K (+2,280.0%) | 766.3K +713.6K (+1,353.7%) | 11.65% +11.161 pp | 0.06% +0.055 pp | USD1.46 -22.6% | 5 qtrs — |
| 4 | ORBIMED ADVISORS LLC | 605.5K +— (+0.0%) | 684.3K -436.0K (-38.9%) | 10.40% +0.000 pp | 0.01% -0.012 pp | USD5.88 -80.8% | 6 qtrs — |
| 5 | BOOTHBAY FUND MANAGEMENT, LLC | 194.5K +194.5K (+100.0%) | 219.8K +219.8K (+100.0%) | 3.34% +3.342 pp | 0.00% +0.003 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 6 | ADAR1 CAPITAL MANAGEMENT, LLC | 154.4K +154.4K (+100.0%) | 174.5K +174.5K (+100.0%) | 2.65% +2.653 pp | 0.01% +0.013 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 7 | VANGUARD GROUP INC | 87.3K +— (+0.0%) | 98.6K -62.8K (-38.9%) | 1.50% +0.000 pp | 0.00% +0.000 pp | USD2.46 -54.1% | 6 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 61.7K +18.2K (+41.9%) | 69.7K -10.7K (-13.3%) | 1.06% +0.313 pp | 0.00% +0.000 pp | USD4.09 -72.4% | 5 qtrs — |
| 9 | XTX TOPCO LTD | 42.2K +31.5K (+294.2%) | 47.7K +27.9K (+140.8%) | 0.73% +0.541 pp | 0.00% +0.000 pp | USD1.31 -13.7% | 2 qtrs — |
| 10 | STATE STREET CORP | 25.8K +25.8K (+100.0%) | 29.2K +29.2K (+100.0%) | 0.44% +0.443 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 11 | CITADEL ADVISORS LLC | 24.8K +24.8K (+100.0%) | 28.0K +28.0K (+100.0%) | 0.43% +0.426 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 12 | TWO SIGMA INVESTMENTS, LP | 19.2K -2.8K (-12.6%) | 21.7K -19.0K (-46.6%) | 0.33% -0.048 pp | 0.00% +0.000 pp | USD1.58 -28.5% | 3 qtrs — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 14.2K +14.2K (+100.0%) | 16.0K +16.0K (+100.0%) | 0.24% +0.244 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 14 | BLACKROCK, INC. | 10.0K +— (+0.0%) | 11.3K -7.2K (-38.9%) | 0.17% +0.000 pp | 0.00% +0.000 pp | USD5.88 -80.8% | 6 qtrs — |
| 15 | UBS GROUP AG | 7.7K +7.7K (+128,600.0%) | 8.7K +8.7K (+79,227.3%) | 0.13% +0.133 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 6 qtrs — |
| 16 | SBI SECURITIES CO., LTD. | 162.00 +— (+0.0%) | 183.00 -117.0 (-39.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.31 -73.8% | 5 qtrs — |
| 17 | BANK OF AMERICA CORP /DE/ | 113.00 +11.0 (+10.8%) | 128.00 -61.0 (-32.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.41 -74.4% | 6 qtrs — |
| 18 | ADVISOR GROUP HOLDINGS, INC. | 8.00 +8.0 (+100.0%) | 9.00 +9.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 19 | FMR LLC | 2.00 +— (+0.0%) | 2.00 -2.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -43.5% | 4 qtrs — |
| 20 | CITIGROUP INC | 1.00 -3.5K (-100.0%) | 1.00 -6.5K (-100.0%) | 0.00% -0.061 pp | 0.00% +0.000 pp | USD1.00 +13.0% | 3 qtrs — |
| 21 | MORGAN STANLEY | — -719.0 (-100.0%) | — -1.3K (-100.0%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 22 | VESTAL POINT CAPITAL, LP | — -150.0K (-100.0%) | — -277.5K (-100.0%) | 0.00% -2.577 pp | 0.00% -0.013 pp | USD— | 5 qtrs SOLD |
| 23 | ASSETMARK, INC | — -2.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 24 | VERMILLION & WHITE WEALTH MANAGEMENT GROUP, LLC | — -96.0 (-100.0%) | — -178.0 (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 25 | HRT FINANCIAL LP | — -12.6K (-100.0%) | — -23.0K (-100.0%) | 0.00% -0.216 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 78.8K | 0.05% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 121.81 | 0.05% |
| 3 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 0.10 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 1.34 | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 0.49 | 0.03% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 230.00 | 0.03% |
| 7 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | — | 0.31% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | — | 0.22% |
| 9 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | — | 0.22% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | — | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
9
Sells
0
Shares acquired
720.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+720,454
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Series C Warrants (right to buy) | 1,793,187 | 1.67 | 3.00M | 1,793,187 | I | ↗ |
| 2026-03-08 | Shoemaker Mary Teresa | Director | A-Award | A | Stock Option (right to buy) | 33,435 | 1.60 | 53.5K | 33,435 | D | ↗ |
| 2026-03-08 | Savchuk Nikolay | Director / Officer | A-Award | A | Stock Option (right to buy) | 96,899 | 1.60 | 155.0K | 96,899 | D | ↗ |
| 2026-03-08 | STOVER JACK E | Director | A-Award | A | Stock Option (right to buy) | 33,435 | 1.60 | 53.5K | 33,435 | D | ↗ |
| 2026-03-08 | Redfield Robert | Officer | A-Award | A | Stock Option (right to buy) | 108,854 | 1.60 | 174.2K | 108,854 | D | ↗ |
| 2026-03-08 | Pauza Charles David | Officer | A-Award | A | Stock Option (right to buy) | 118,367 | 1.60 | 189.4K | 118,367 | D | ↗ |
| 2026-03-08 | Parker Charles Nolan | Officer | A-Award | A | Stock Option (right to buy) | 104,544 | 1.60 | 167.3K | 104,544 | D | ↗ |
| 2026-03-08 | Leaman John Harold | Director | A-Award | A | Stock Option (right to buy) | 33,435 | 1.60 | 53.5K | 33,435 | D | ↗ |
| 2026-03-08 | Dukes Iain D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 231,336 | 1.60 | 370.1K | 231,336 | D | ↗ |
| 2026-03-08 | Clarke Trafford | Director | A-Award | A | Stock Option (right to buy) | 33,435 | 1.60 | 53.5K | 33,435 | D | ↗ |
| 2026-03-08 | CAUTREELS WERNER | Director | A-Award | A | Stock Option (right to buy) | 31,258 | 1.60 | 50.0K | 31,258 | D | ↗ |
| 2025-12-12 | Shoemaker Mary Teresa | Director | A-Award | A | Common Stock | 6,157 | 0.00 | — | 6,292 | D | ↗ |
| 2025-12-12 | Savchuk Nikolay | Director / Officer | A-Award | A | Common Stock | 16,419 | 0.00 | — | 150,606 | D | ↗ |
| 2025-12-12 | STOVER JACK E | Director | A-Award | A | Common Stock | 6,157 | 0.00 | — | 6,165 | D | ↗ |
| 2025-12-12 | Redfield Robert | Officer | A-Award | A | Common Stock | 16,419 | 0.00 | — | 113,919 | D | ↗ |
| 2025-12-12 | Pauza Charles David | Officer | A-Award | A | Stock Option (right to purchase) | 73,886 | 2.33 | 172.2K | 73,886 | D | ↗ |
| 2025-12-12 | Parker Charles Nolan | Officer | A-Award | A | Common Stock | 15,393 | 0.00 | — | 15,393 | D | ↗ |
| 2025-12-12 | Leaman John Harold | Director | A-Award | A | Common Stock | 4,058 | 0.00 | — | 4,058 | D | ↗ |
| 2025-12-12 | Dukes Iain D. | Director / Officer | A-Award | A | Stock Option (right to purchase) | 147,771 | 2.33 | 344.3K | 147,771 | D | ↗ |
| 2025-12-12 | Clarke Trafford | Director | A-Award | A | Common Stock | 6,157 | 0.00 | — | 6,157 | D | ↗ |
| 2025-12-12 | CAUTREELS WERNER | Director | A-Award | A | Common Stock | 4,874 | 0.00 | — | 109,222 | D | ↗ |
| 2025-11-21 | Leaman John Harold | Director | A-Award | A | Stock Option (right to purchase) | 12,770 | 2.31 | 29.5K | 12,770 | D | ↗ |
| 2025-10-12 | Shoemaker Mary Teresa | Director | A-Award | A | Stock Option (right to purchase) | 11,530 | 3.01 | 34.7K | 11,530 | D | ↗ |
| 2025-10-12 | Savchuk Nikolay | Director / Officer | A-Award | A | Stock Option (right to purchase) | 22,435 | 3.01 | 67.5K | 22,435 | D | ↗ |
| 2025-10-12 | STOVER JACK E | Director | A-Award | A | Stock Option (right to purchase) | 11,530 | 3.01 | 34.7K | 11,530 | D | ↗ |
| 2025-10-12 | Redfield Robert | Officer | A-Award | A | Stock Option (right to purchase) | 32,406 | 3.01 | 97.5K | 32,406 | D | ↗ |
| 2025-10-12 | Pauza Charles David | Officer | A-Award | A | Stock Option (right to purchase) | 32,406 | 3.01 | 97.5K | 32,406 | D | ↗ |
| 2025-10-12 | Parker Charles Nolan | Officer | A-Award | A | Stock Option (right to buy) | 32,406 | 3.01 | 97.5K | 32,406 | D | ↗ |
| 2025-10-12 | Dukes Iain D. | Director / Officer | A-Award | A | Stock Option (right to purchase) | 64,839 | 3.01 | 195.2K | 64,839 | D | ↗ |
| 2025-10-12 | Clarke Trafford | Director | A-Award | A | Stock Option (right to purchase) | 11,530 | 3.01 | 34.7K | 11,530 | D | ↗ |
| 2025-10-12 | CAUTREELS WERNER | Director | A-Award | A | Stock Option (right to purchase) | 11,530 | 3.01 | 34.7K | 11,530 | D | ↗ |
| 2025-10-01 | Leaman John Harold | Director | A-Award | A | Stock Option (right to purchase) | 15,609 | 1.89 | 29.5K | 15,609 | D | ↗ |
| 2025-07-03 | Parker Charles Nolan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-19 | Shoemaker Mary Teresa | Director | A-Award | A | Stock Option (right to purchase) | 23,000 | 1.65 | 38.0K | 23,000 | D | ↗ |
| 2025-06-19 | STOVER JACK E | Director | A-Award | A | Stock Option (right to purchase) | 23,000 | 1.65 | 38.0K | 23,000 | D | ↗ |
| 2025-06-19 | Clarke Trafford | Director | A-Award | A | Stock Option (right to purchase) | 23,000 | 1.65 | 38.0K | 23,000 | D | ↗ |
| 2025-06-19 | CAUTREELS WERNER | Director | A-Award | A | Stock Option (right to purchase) | 23,000 | 1.65 | 38.0K | 23,000 | D | ↗ |
| 2025-04-02 | TPAV, LLC | 10% Owner | J-Other | D | Common Stock | 605,531 | 0.00 | — | 0 | D | ↗ |
| 2025-02-18 | CAUTREELS WERNER | Director / Officer | M-Exempt | A | Common Stock | 96,348 | 0.01 | 963.48 | 104,348 | D | ↗ |
| 2025-02-05 | Guerin Mark Patrick | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-05 | Brennan Nora | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-29 | TPAV, LLC | 10% Owner | P-Purchase | A | Series A Warrant (right to buy) | 96,348 | 13.42 | 1.29M | 96,348 | D | ↗ |
| 2024-12-29 | Savchuk Nikolay | Director / Officer / 10% Owner | P-Purchase | A | Series A Warrant (right to buy) | 96,348 | 13.42 | 1.29M | 96,348 | I | ↗ |
| 2024-12-29 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Series A Warrant (right to buy) | 96,348 | 13.42 | 1.29M | 96,348 | I | ↗ |
| 2024-12-29 | CAUTREELS WERNER | Director / Officer | P-Purchase | A | Pre-Funded Warrant (right to buy) | 96,348 | 0.01 | 963.48 | 96,348 | D | ↗ |
| 2024-09-16 | ORBIMED ADVISORS LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 602,000 | I | ↗ |
| 2024-09-16 | Greenwood Luba | Director | A-Award | A | Stock Option (Right to Purchase) | 164,000 | 0.34 | 55.8K | 164,000 | — | ↗ |
| 2024-06-18 | Guerin Mark Patrick | Officer | F-InKind | D | Common Stock | 2,221 | 0.47 | 1.0K | 39,255 | — | ↗ |
| 2024-06-10 | Guerin Mark Patrick | Officer | M-Exempt | A | Common Stock | 5,500 | 0.00 | — | 41,476 | — | ↗ |
| 2024-04-03 | Viriom, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,645,100 | — | ↗ |
| 2024-04-01 | TPAV, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 885,532 | — | ↗ |
| 2024-04-01 | Savchuk Nikolay | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-01 | Redfield Robert | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-01 | Pauza Charles David | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-01 | ORBIMED ADVISORS LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 885,532 | — | ↗ |
| 2024-04-01 | Dukes Iain D. | Director / Officer | A-Award | A | Common Stock | 66,687 | 0.01 | 666.87 | 66,687 | — | ↗ |
| 2024-04-01 | CAUTREELS WERNER | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-29.8K
Shares Outstanding
9.14M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Werner Cautreels, Ph.D. Former Chief Executive Officer | 445.8K | — | 200.0K | — | — | 1.8K | 647.6K | 30.88% | ↗ |
| 2 | 2024 | Mark P. Guerin Former Chief Financial Officer and Chief Operating Officer | 520.9K | — | — | — | — | 41.9K | 562.7K | 0.00% | ↗ |
| 3 | 2024 | Victor Moyo, M.D. Chief Medical Officer – Oncology | 453.1K | — | — | — | — | 25.3K | 478.4K | 0.00% | ↗ |
| 4 | 2024 | Steven M. Fruchtman, M.D. Former President and Chief Executive Officer | 332.9K | — | — | — | — | 77.1K | 410.0K | 0.00% | ↗ |
| 5 | 2023 | Steven M. Fruchtman, M.D. Former President and Chief Executive Officer | 660.9K | 227.4K | 50.6K | 131.7K | — | 36.2K | 1.11M | 16.47% | ↗ |
| 6 | 2023 | Steven M. Fruchtman, M.D. President and Chief Executive Officer | 660.3K | 232.5K | 50.6K | 131.7K | — | 26.3K | 1.10M | 16.55% | ↗ |
| 7 | 2023 | Mark P. Guerin Chief Operating Officer and Chief Financial Officer | 500.1K | 143.9K | 19.0K | 50.2K | — | 32.3K | 745.5K | 9.29% | ↗ |
| 8 | 2023 | Mark P. Guerin Former Chief Financial Officer and Chief Operating Officer | 500.7K | 137.8K | 19.0K | 50.2K | — | 37.0K | 744.7K | 9.30% | ↗ |
| 9 | 2023 | Victor Moyo, M.D. Chief Medical Officer | 103.8K | 117.1K | — | 78.6K | — | 105.6K | 405.3K | 19.40% | ↗ |
| 10 | 2023 | Victor Moyo, M.D. Chief Medical Officer – Oncology | 103.8K | 114.0K | — | 78.6K | — | 108.2K | 404.7K | 19.43% | ↗ |
| 11 | 2022 | Steven M. Fruchtman, M.D. President and Chief Executive Officer | 630.0K | 251.8K | 116.4K | 302.5K | — | 26.1K | 1.33M | 31.57% | ↗ |
| 12 | 2022 | Mark P. Guerin Chief Operating Officer and Chief Financial Officer | 452.0K | 144.4K | 59.6K | 155.8K | — | 32.9K | 844.7K | 25.50% | ↗ |
| 13 | 2022 | Mark S. Gelder, M.D. Chief Medical Officer | 425.0K | 131.7K | 31.9K | 81.6K | — | 7.5K | 677.6K | 16.74% | ↗ |
| 14 | 2021 | Steven M. Fruchtman, M.D. President and Chief Executive Officer | 600.0K | 279.8K | 1.26M | 509.1K | — | 23.7K | 2.67M | 66.22% | ↗ |
| 15 | 2021 | Mark P. Guerin Chief Financial Officer | 400.0K | 149.2K | 528.4K | 192.7K | — | 29.2K | 1.30M | 55.49% | ↗ |
| 16 | 2021 | Mark P. Guerin Chief Operating Officer and Chief Financial Officer | 400.0K | 149.2K | 528.4K | 192.7K | — | 29.2K | 1.30M | 55.49% | ↗ |
| 17 | 2021 | Abraham N. Oler Senior Vice President, Corporate Development and General Counsel | 375.0K | 139.9K | 383.6K | 180.1K | — | 14.7K | 1.09M | 51.56% | ↗ |
| 18 | 2020 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 451.5K | 109.4K | 38.8K | — | — | 558.6K | 1.18M | 3.29% | ↗ |
| 19 | 2020 | Steven M. Fruchtman, M.D. President and Chief Executive Officer | 562.2K | 266.7K | 118.2K | 61.5K | — | 23.2K | 1.03M | 17.41% | ↗ |
| 20 | 2020 | Mark P. Guerin Chief Financial Officer | 374.8K | 142.2K | 50.4K | 26.2K | — | 28.5K | 622.1K | 12.31% | ↗ |
| 21 | 2020 | Mark Guerin Chief Financial Officer | 374.8K | 108.9K | 50.4K | — | — | 28.5K | 588.8K | 8.55% | ↗ |
| 22 | 2020 | Richard C. Woodman, M.D. Chief Medical Officer and Senior Vice President, Research and Development | 393.8K | 99.8K | 36.7K | — | — | 2.2K | 551.5K | 6.66% | ↗ |
| 23 | 2019 | Ramesh Kumar, Ph.D. Former President and Chief Executive Officer | 88.7K | 254.9K | — | — | — | 864.0K | 1.21M | 0.00% | ↗ |
| 24 | 2019 | Steven M. Fruchtman, M.D. President and Chief Executive Officer | 509.2K | 191.5K | — | — | — | 21.8K | 772.5K | 0.00% | ↗ |
| 25 | 2019 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 416.8K | 133.6K | — | — | — | 14.9K | 576.1K | 0.00% | ↗ |
| 26 | 2019 | Mark Guerin Chief Financial Officer | 353.6K | 108.8K | — | — | — | 26.5K | 505.1K | 0.00% | ↗ |
| 27 | 2019 | Richard C. Woodman, M.D. Chief Medical Officer and Senior Vice President, Research and Development | 375.0K | 18.7K | — | — | — | 11.6K | 425.3K | 0.00% | ↗ |
| 28 | 2018 | Ramesh Kumar, Ph.D. Chief Executive Officer | 569.4K | 136.0K | — | 441.9K | — | 27.3K | 1.17M | 37.62% | ↗ |
| 29 | 2018 | Ramesh Kumar, Ph.D. Former President and Chief Executive Officer | 569.4K | 136.0K | — | 441.9K | — | 27.3K | 1.17M | 37.62% | ↗ |
| 30 | 2018 | Steven M. Fruchtman, M.D. President and Chief Medical Officer | 460.8K | 322.3K | — | 164.4K | — | 22.6K | 970.1K | 16.94% | ↗ |
| 31 | 2018 | Steven M. Fruchtman, M.D. President and Chief Executive Officer | 460.8K | 322.3K | — | 164.4K | — | 22.6K | 691.0K | 23.78% | ↗ |
| 32 | 2018 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 410.3K | 109.1K | — | 131.3K | — | 25.4K | 676.2K | 19.42% | ↗ |
| 33 | 2017 | Ramesh Kumar, Ph.D. President and Chief Executive Officer | 538.2K | — | — | 81.9K | — | 23.6K | 643.6K | 12.72% | ↗ |
| 34 | 2017 | Ramesh Kumar, Ph.D. Chief Executive Officer | 538.2K | — | — | 81.9K | — | 23.6K | 643.6K | 12.72% | ↗ |
| 35 | 2017 | Steven M. Fruchtman, M.D. President and Chief Medical Officer | 436.2K | — | — | 49.1K | — | 19.3K | 504.6K | 9.73% | ↗ |
| 36 | 2017 | Steven M. Fruchtman, M.D. Chief Medical Officer and Senior Vice President, Research and Development | 436.2K | — | — | 49.1K | — | 19.3K | 504.6K | 9.73% | ↗ |
| 37 | 2017 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 389.0K | — | — | 36.1K | — | 14.4K | 439.5K | 8.22% | ↗ |
| 38 | 2016 | Ramesh Kumar, Ph.D. President and Chief Executive Officer | 413.2K | 254.0K | — | 177.7K | — | 19.7K | 864.6K | 20.56% | ↗ |
| 39 | 2016 | Steven M. Fruchtman, M.D. Chief Medical Officer and Senior Vice President, Research and Development | 421.8K | 142.8K | — | 119.3K | — | 7.2K | 691.0K | 17.26% | ↗ |
| 40 | 2016 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 371.5K | 126.2K | — | 89.7K | — | 11.9K | 599.3K | 14.97% | ↗ |
| 41 | 2015 | Steven M. Fruchtman, M.D. Chief Medical Officer and Senior Vice President, Research and Development | 395.8K | 50.0K | — | 459.9K | — | 7.5K | 913.2K | 50.36% | ↗ |
| 42 | 2015 | Ramesh Kumar, Ph.D. President and Chief Executive Officer | 542.8K | — | — | 224.1K | — | 13.0K | 779.8K | 28.73% | ↗ |
| 43 | 2015 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 370.7K | — | — | 102.4K | — | 20.0K | 493.1K | 20.77% | ↗ |
| 44 | 2014 | Ramesh Kumar, Ph.D. President and Chief Executive Officer | 525.0K | 188.4K | — | 485.0K | — | 18.8K | 1.22M | 39.84% | ↗ |
| 45 | 2014 | Manoj Maniar, Ph.D. Senior Vice President, Product Development | 356.9K | 108.7K | — | 166.3K | — | 30.6K | 662.4K | 25.10% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Iain D. Dukes DPHIL | Chief Executive Officer, Secretary & Director | 776.4K | — |
| Charles David Pauza | Chief Scientific Officer of Virology | 701.3K | — |
| Charles Parker | Chief Financial Officer | 676.3K | male |
| Victor Moyo | Chief Medical Officer of Oncology | 478.4K | — |
| Nikolay Savchuk | Chief Operating Officer & Director | 476.0K | — |
| Robert Redfield | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRAW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
